These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23863802)

  • 41. Association between cytochrome P450 3A5 polymorphism and the lung function in Saskatchewan grain workers.
    Seo T; Pahwa P; McDuffie HH; Yurube K; Egoshi M; Umemoto Y; Ghosh S; Fukushima Y; Nakagawa K
    Pharmacogenet Genomics; 2008 Jun; 18(6):487-93. PubMed ID: 18496128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tacrolimus therapeutic efficacy in post-liver transplant patients with Cytochrome P450 3A5 (CYP3A5) genetic polymorphisms.
    Bezerra LS; Santos-Veloso MAO; Oliveira SBL; Dias AAP; Carvalho-Filho ÂT; Gonzaga-Neto PP; Melo PSV
    Rev Col Bras Cir; 2020 Jun; 47():e20202384. PubMed ID: 32578817
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Yamamoto Y; Nakase H; Matsuura M; Maruyama S; Masuda S
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32570960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD; Cho HY; Lee YB
    Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
    Arnett DK; Davis BR; Ford CE; Boerwinkle E; Leiendecker-Foster C; Miller MB; Black H; Eckfeldt JH
    Circulation; 2005 Jun; 111(25):3374-83. PubMed ID: 15967849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
    Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects.
    Han JM; Yee J; Chung JE; Lee KE; Park K; Gwak HS
    Mol Genet Genomic Med; 2020 May; 8(5):e1201. PubMed ID: 32134573
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Gene polymorphisms of CYP3A5 and MDR-1 in Hans renal transplant recipients in Hunan Province].
    Shao M; Ye Q; She X; Liu H; Ye S; Niu Y; Ming Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Aug; 38(8):824-9. PubMed ID: 23981990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of G-protein β-Polypeptide 3 C825T Polymorphism on Antihypertensive Response to Telmisartan and Amlodipine in Chinese Patients.
    Zhang ZL; Li HL; Wen ZP; Yang GP; Zhang W; Chen XP
    Chin Med J (Engl); 2016 Jan; 129(1):8-14. PubMed ID: 26712426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.
    Hoshikawa K; Naito T; Akutsu S; Saotome M; Maekawa Y; Kawakami J
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):353-363. PubMed ID: 31652395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
    Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
    Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.
    Zhu HJ; Yuan SH; Fang Y; Sun XZ; Kong H; Ge WH
    Pharmacogenomics J; 2011 Jun; 11(3):237-46. PubMed ID: 20368718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity.
    Udomkarnjananun S; Townamchai N; Chariyavilaskul P; Iampenkhae K; Pongpirul K; Sirichindakul B; Panumatrassamee K; Vanichanan J; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K
    Am J Nephrol; 2018; 47(3):182-190. PubMed ID: 29539600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
    Kniepeiss D; Renner W; Trummer O; Wagner D; Wasler A; Khoschsorur GA; Truschnig-Wilders M; Tscheliessnigg KH
    Clin Transplant; 2011; 25(1):146-50. PubMed ID: 20041908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
    Anutrakulchai S; Pongskul C; Kritmetapak K; Limwattananon C; Vannaprasaht S
    Br J Clin Pharmacol; 2019 Sep; 85(9):1964-1973. PubMed ID: 31077425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
    Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
    Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.